Natera is trading 5.03% higher at $429.34 as investors respond to Japan’s September 22 approval of Signatera as a companion diagnostic for muscle-invasive bladder cancer.
- The approval supports treatment decisions involving Roche’s atezolizumab and represents Signatera’s second PMDA authorization in Japan.
- Commercial launch is expected in the first half of 2027.
- Natera gained 4.61% to $408.79 on September 24; broader equities were also modestly firmer pre-market, while the regulatory milestone remains the clearest company-specific catalyst.